(Q43634499)

25 November 2017

title

Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study (English)

1 reference

25 November 2017

1 reference

M Saghatchian

1

1 reference

25 November 2017

K Fizazi

2

1 reference

25 November 2017

C Borel

3

1 reference

25 November 2017

M Ducreux

4

1 reference

25 November 2017

P Ruffié

5

1 reference

25 November 2017

T Le Chevalier

6

1 reference

25 November 2017

C Théodore

7

1 reference

25 November 2017

publication date

1 April 2001

1 reference

25 November 2017

1 reference

25 November 2017

volume

12

1 reference

25 November 2017

issue

4

1 reference

25 November 2017

page(s)

535-540

1 reference

25 November 2017

cites work

Unknown primary tumours

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011129429499

7 January 2021

Treatment of patients with cancer of an unknown primary site

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011129429499

7 January 2021

Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011129429499

7 January 2021

Axillary lymph node metastases in patients with occult noninvasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011129429499

7 January 2021

Carcinoma of unknown primary: Identification of a treatable subset?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011129429499

7 January 2021

Mitomycin C, Epirubicin and Cisplatin versus Mitomycin C Alone as Therapy for Carcinoma of Unknown Primary Origin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011129429499

7 January 2021

Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011129429499

7 January 2021

Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011129429499

7 January 2021

The Unrecognized Extragonadal Germ Cell Cancer Syndrome

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011129429499

7 January 2021

Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti-neoplastic agents

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011129429499

7 January 2021

Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011129429499

7 January 2021

Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011129429499

7 January 2021

5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011129429499

7 January 2021

5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011129429499

7 January 2021

Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011129429499

7 January 2021

Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011129429499

7 January 2021

Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011129429499

7 January 2021

Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011129429499

7 January 2021

Identifiers

DOI

10.1023/A:1011129429499

1 reference

25 November 2017

1 reference